Russia announces that it has developed a new cancer vaccine

Home Sectors Health


Russia  announces that it has developed  a new cancer vaccine,  which will be distributed free  of charge in  2025
Russia announces that it has developed  a new cancer vaccine,  which will be distributed free  of charge in  2025.
The Russian  Ministry of Health has announced that it has developed a cancer  vaccine, which will be distributed free of charge  to patients in early  2025.
The vaccine not only  slows down the progression  of the tumor, but also  reduces the size of the tumor by 75-80%.
Andrey Kaprin,  director of the Medical Research Center  of Radiology at the Russian Ministry of Health, confirmed that the cancer vaccine will be launched in early  2025.
Unlike preventive vaccines, which aim to  prevent the development of tumors in healthy individuals, this vaccine  aims to treat existing  cases of cancer.
Russian government scientists have suggested  that, like cancer treatments developed in Western countries, the vaccine  could be personalized for each patient. This personalized approach aims to tailor the vaccine to the specific  type of cancer and  the individual characteristics of each  patient.

A trip through Quang Binh to  breathtaking movie locations
Vaccine details unclear
While the announcement has  caused excitement, many details remain  unclear.
It is  still not  clear what types of cancer the vaccine is designed to treat, how effective it will  be or how the Russian government plans to  use it. The name of the vaccine has not  yet been  disclosed.
Alexander Gintsburg's  views on  vaccination
Alexander Gintsburg,  director of the Gamaleya  research center in Russia,  emphasized: "This is not a universal vaccine.  "It is a personalized vaccine, not only for each type of  cancer, but also for  any type of  cancer. It is a therapeutic vaccine and does not protect against infectious diseases. It treats  people suffering from oncological  diseases. »
The news follows after this  announcement
How the  vaccine works
Gintsburg also explained that this drug or vaccine is a  bit "vulgar", figuratively speaking. It directs the  patient's immune system against malignant  cells, because this vaccine carries in its composition  the changes that are characteristic at the genetic level of  tumors.
"As a result, the  patient's immune system recognizes these cells, which carry  cancer markers, and begins to destroy them with cytotoxic  lymphocytes - special immune cells that essentially devour  cells carrying tumor markers. "So that's the  point of this vaccine," he  explained.
Collaboration with leading cancer centers
At the Gamaleya Institute, Gintsburg and his team  collaborate with colleagues from two leading cancer centers: the Herzen Center,  headed by Professor Caprin, and the Blokken Center, headed by Academician Stilidi. They also  work with young colleagues from the Serious  Center.
"A system has been created that allows us to genetically  transfer the necessary genetic sequences  into our eukaryotic cells," Gintsburg explained. These methods and technologies are  fully covered by  national patents, which  allows us to use them widely and openly to create  medicines. »
Focus on melanoma vaccine prototypes.  The first  goal is to focus on  vaccine prototypes created against melanoma, the most malignant and  serious oncological  disease.
Gintsburg explained that the mouse melanoma model shows that three variants  of vaccines created  with these technologies protect these animals from  immediate death.
Global efforts in personalized cancer  vaccines
Meanwhile, other countries are also working on their own personalized cancer vaccines, highlighting  the growing global interest in this promising area of  cancer treatment.

[attachment deleted by admin]